1-7 of 7
Susan M. O'Brien
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

Open Access
Mazyar Shadman, Jennifer R. Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan M. O'Brien, Alessandra Tedeschi, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2025) 9 (12): 2863–2870.
https://doi.org/10.1182/bloodadvances.2024014523
Published: 2025
Includes: Supplemental data
Journal Articles

Real-World Survival Outcomes in First-Line Ibrutinib-Treated Patients with High-Risk CLL/SLL

Open Access
Clinical Trials & Observations
John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P. Qureshi, Susan M. O'Brien
Journal: Blood Advances
Blood Adv bloodadvances.2024015417.
https://doi.org/10.1182/bloodadvances.2024015417
Published: 2025
Journal Articles

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

Open Access
Clinical Trials & Observations
Jennifer R. Brown, Jessica Li, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O’Brien, Constantine S. Tam, Lugui Qiu, Ruiqi Huang, Yang Shi, Adam Idoine, Tommi Salmi, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood Advances
Blood Adv (2025) 9 (8): 1918–1926.
https://doi.org/10.1182/bloodadvances.2024014206
Published: 2025
Includes: Supplemental data
Journal Articles

Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph + acute lymphoblastic leukemia

Free
Clinical Trials & Observations
Anjali S. Advani, Anna Moseley, Kristen M. O’Dwyer, Brent L. Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab L. Atallah, Aaron T. Gerds, Susan M. O'Brien, Jane L. Liesveld, Megan Othus, Mark Litzow, Richard M. Stone, Elad Sharon, Harry P. Erba
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1279–1285.
https://doi.org/10.1182/bloodadvances.2022008216
Published: 2023
Includes: Supplemental data
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Free
Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data
Journal Articles

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

Free
Clinical Trials & Observations
Paolo Strati, Koichi Takahashi, Christine B. Peterson, Michael J. Keating, Philip A. Thompson, Naval G. Daver, Nitin Jain, Jan A. Burger, Zeev Estrov, Susan M. O'Brien, Hagop M. Kantarjian, William G. Wierda, P. Andrew Futreal, Alessandra Ferrajoli
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1533–1539.
https://doi.org/10.1182/bloodadvances.2019031336
Published: 2019
Journal Articles

US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL

Free
Clinical Trials & Observations
Farhad Ravandi, Megan Othus, Susan M. O'Brien, Stephen J. Forman, Chul S. Ha, Jeffrey Y. C. Wong, Martin S. Tallman, Elisabeth Paietta, Janis Racevskis, Geoffrey L. Uy, Mary Horowitz, Naoko Takebe, Richard Little, Uma Borate, Partow Kebriaei, Laura Kingsbury, Hagop M. Kantarjian, Jerald P. Radich, Harry P. Erba, Frederick R. Appelbaum
Journal: Blood Advances
Blood Adv (2016) 1 (3): 250–259.
https://doi.org/10.1182/bloodadvances.2016001495
Published: 2016
Includes: Supplemental data